Abstract In order to prevent long-term immunity-related complications after lung transplantation, close monitoring of immunosuppressant levels using therapeutic drug monitoring (TDM) is paramount. Novel electronic nose (eNose) technology may be a non-invasive alternative to the current invasive procedures for TDM. We investigated the diagnostic and categorization capacity of eNose breathprints for Tacrolimus trough blood plasma levels (TAC_trough) in lung transplant recipients (LTRs). We performed eNose measurements in stable LTR attending the outpatient clinic. We evaluated (1) the correlation between eNose measurements and TAC_trough, (2) the diagnostic capacity of eNose technology for TAC_trough, and (3) the accuracy of eNose technology for categorization of TAC_trough into three clinically relevant categories (low: <7 µg ml⁻¹, medium: 7–10 µg ml⁻¹, and high: >10 µg ml⁻¹ ). A total of 186 measurements from 86 LTR were included. There was a weak but statistically significant correlation (r = 0.21, p = 0.004) between the eNose measurements and TAC_trough. The root mean squared error of prediction for the diagnostic capacity was 3.186 in the training and 3.131 in the validation set. The accuracy of categorization ranged between 45%–63% for the training set and 52%–69% in the validation set. There is a weak correlation between eNose breathprints and TAC_trough in LTR. However, the diagnostic as well as categorization capacity for TAC_trough using eNose breathprints is too inaccurate to be applicable in TDM.